5 Easy Steps To Choose Effectively A Fda Attorney

Jessie Smith, a Senior Deputy Attorney General for Pennsylvania, says the $19.5 million settlement with Bristol Myers-Squibb settles complaints about deceptive marketing of the drug to doctors and patients. They were marketing it for many things beyond schizophrenia, which was its indication when it fist went on to the market in 2002, including uses for children, said Smith. Smith says the drug was never approved by the Food and Drug Administration for children. She says Bristol Myers-Squibb also promoted Abilify for patients with dementia and Alzheimers, without FDA approvals. In fact, she

...